Loading
NASDAQHealthcareBiotechnology
Latest quote
$1.81
+$0.04 · +2.26%
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Previous close
$1.81
+$0.04 · +2.26%
Regular session · ET · Market data may be delayed.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Day range
Current $1.81
52-week range
Current $1.81
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
58
Fair Value
Sentiment
39
Bearish
Risk
73
High Risk
Momentum
48
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Day range
Current $1.81
52-week range
Current $1.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 75.56M USD | 10.12M USD | 1.7M USD | 6.19M USD | 1.51M USD |
| Cost of goods sold | 96.59M USD | 141.02M USD | — | — | — |
| Gross profit | −21.03M USD | −130.9M USD | 1.7M USD | 6.19M USD | 1.51M USD |
| Research and development | 128.59M USD | 158.14M USD | 130.48M USD | 117.35M USD | 110.84M USD |
| Selling, general, and administrative | 131.82M USD | — | 46.75M USD | 31.9M USD | 31.87M USD |
| Operating expenses | 260.41M USD | 110.53M USD | 181.4M USD | 149.09M USD | 141.88M USD |
| Interest income | 19.02M USD | 32.36M USD | 13.51M USD | 1.71M USD | 262K USD |
| Interest expense | 36.76M USD | 9.29M USD | 45.07M USD | 8.91M USD | 1.11M USD |
| Depreciation and amortization | 9.81M USD | 7.72M USD | 6.57M USD | 7.42M USD | 8.46M USD |
| Operating income | −281.44M USD | −241.43M USD | −179.7M USD | −142.89M USD | −140.37M USD |
| Net income | −288.2M USD | −220.66M USD | −208.38M USD | −148.84M USD | −142.1M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB2.35M0.02%10.82B USD0.44%$206.49+3.00%
Tema Oncology ETFCANC500.22K0.24%205.09M USD0.99%$40.7829+1.63%
State Street SPDR S&P International Small Cap ETFGWX180.46K0.02%907.87M USD0.40%$45.56+0.93%
Invesco NASDAQ Future Gen 200 ETFQQQS91.84K0.40%22.76M USD0.20%$42.145+1.39%
ActivePassive International Equity ETFAPIE57.39K0.01%1.14B USD0.45%$38.56+0.65%
Invesco Nasdaq Biotechnology ETFIBBQ27K0.02%111.67M USD0.19%$34.62+2.96%
ProShares Ultra Nasdaq BiotechnologyBIB13.95K0.01%93.2M USD1.19%$110.98+5.68%iShares Biotechnology ETFIBBTema Oncology ETFCANCState Street SPDR S&P International Small Cap ETFGWXInvesco NASDAQ Future Gen 200 ETFQQQSActivePassive International Equity ETFAPIEInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
